CD274 and head and neck cancer: Synergy has been observed when combining anti-PD-L1 with radiotherapy in various cancers [24], however, evidence from preclinical models and clinical trials in head and neck cancers has shown reduced or minimal synergistic efficacy, highlighting the need for optimization of treatment strategies [17,25].